Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3181
-$0.0359-10.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -89.76% | -80.98% | -78.55% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.76% | -80.98% | -78.55% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -89.76% | -80.98% | -78.55% | -- | 108.50% |
| SG&A Expenses | -19.67% | -9.56% | -9.56% | -10.29% | -8.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.44% | -46.77% | -29.89% | -19.28% | -6.45% |
| Operating Income | 52.84% | 46.31% | 29.26% | 20.86% | 7.97% |
| Income Before Tax | 53.06% | 45.15% | 27.97% | 18.23% | 1.40% |
| Income Tax Expenses | 73.90% | 42.29% | 36.55% | 38.15% | 36.49% |
| Earnings from Continuing Operations | 50.29% | 45.63% | 26.34% | 13.96% | -6.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.29% | 45.63% | 26.34% | 13.96% | -6.40% |
| EBIT | 52.84% | 46.31% | 29.26% | 20.86% | 7.97% |
| EBITDA | 52.80% | 46.30% | 29.25% | 20.86% | 7.97% |
| EPS Basic | 80.33% | 62.27% | 39.11% | 23.28% | 4.49% |
| Normalized Basic EPS | 78.41% | 62.21% | 41.19% | 28.09% | 11.55% |
| EPS Diluted | 80.33% | 62.27% | 39.11% | 23.28% | 4.49% |
| Normalized Diluted EPS | 78.41% | 62.21% | 41.19% | 28.09% | 11.55% |
| Average Basic Shares Outstanding | 330.25% | 82.28% | 44.16% | 20.92% | 12.36% |
| Average Diluted Shares Outstanding | 330.25% | 82.28% | 44.16% | 20.92% | 12.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 0.54% | 0.32% | 0.13% | 0.06% |